Treatment Resistant Depression Trd Market

DelveInsight’s ‘Treatment-resistant Depression (TRD) —Market Insights, Epidemiology, and Market Forecast—2032’ report deliver an in-depth understanding of Treatment-resistant Depression (TRD), historical and forecasted epidemiology, as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

The Treatment-resistant Depression (TRD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted Treatment-resistant Depression (TRD) symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Treatment-resistant Depression (TRD) symptoms treatment practice/algorithm and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Treatment-resistant Depression (TRD) Understanding and Treatment Algorithm

Treatment-resistant Depression (TRD) Overview

Treatment-resistant Depression (TRD) typically refers to inadequate response to at least two antidepressant medications used for a sufficient length of time at an adequate dose with an adequate affirmation of treatment adherence. TRD is a relatively common occurrence in clinical practice, with up to 50–60% of the patients not achieving adequate response following antidepressant treatment.

 

Treatment-resistant Depression (TRD) Diagnosis and Treatment

This section covers the details of diagnostic methods and conventional and current medical therapies available in the Treatment-resistant Depression (TRD) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

The DelveInsight Treatment-resistant Depression (TRD) market report gives a holistic understanding of Treatment-resistant Depression (TRD) clinical manifestations by including disease definition, symptoms, causes, risk factors, physiology, and diagnosis. It also provides Treatment-resistant Depression (TRD) treatment algorithms and treatment guidelines for Treatment-resistant Depression (TRD) in the US, Europe, and Japan.

 

Pharmacologic treatment options include switching, combination, and potentiation strategies among commonly used antidepressant drugs. Most of the available antidepressants such as selective serotonin reuptake inhibitors (SSRIs), dual serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, irreversible, non-selective monoamine oxidase inhibitors (MAOIs), α2-antagonists, Agomelatine, and Tianeptine are used to treat TRD.

 

Non-pharmacological therapies include electroconvulsive therapy (ECT), Repetitive transcranial magnetic stimulation (rTMS), and Vagus nerve stimulation (VNS). Along with this, two alternative forms of psychotherapy involve majorly cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT). 

Treatment-resistant Depression (TRD) Epidemiology

The Treatment-resistant Depression (TRD) symptoms epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

 

Key Findings

The total prevalent cases of Treatment-resistant Depression (TRD) patients in the 7MM increase during the study period, 2019–2032.

 

The disease epidemiology covered in the report provides historical as well as forecasted Treatment-resistant Depression (TRD) symptoms epidemiology segmented as the Total Diagnosed Prevalence, Gender-specific Cases, and Age-specific Cases. The report includes the prevalent cases scenario of Treatment-resistant Depression (TRD) in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Treatment-resistant Depression (TRD) Epidemiology

The epidemiology segment also provides the Treatment-resistant Depression (TRD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total number of prevalent cases of Treatment-resistant Depression (TRD) in 7MM countries was 5,801,906 in 2021.

Treatment-resistant Depression (TRD) Drug Chapters

The Treatment-resistant Depression (TRD) report’s drug chapter segment encloses the detailed analysis of Treatment-resistant Depression (TRD) early-stage (Phase I, II, and III) pipeline drugs. It also helps understand the Treatment-resistant Depression (TRD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Treatment-resistant Depression (TRD) Emerging Drugs

 

AXS-05: Axsome Therapeutics

AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. It consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion and is being developed to treat central nervous system (CNS) conditions. The FDA granted Priority Review to Axsome Therapeutics’ AXS-05 (dextromethorphan-bupropion). The accelerated review framework shortens the review duration from a standard 10-month period to 6 months after its New Drug Application (NDA) acceptance.

 

VRAYLAR (Cariprazine): AbbVie

Cariprazine is an oral, once-daily atypical antipsychotic. It is a potent central dopamine D3 and D2 receptor partial agonist, which preferentially binds to the D3 receptor. It also has partial agonist activity at serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. Pharmacodynamic studies with cariprazine have shown that it acts as a partial agonist with a high binding affinity at dopamine D3, dopamine D2, and serotonin 5-HT1A receptors. Cariprazine demonstrated up to eightfold greater in vitro affinity for dopamine D3 vs. D2 receptors. Cariprazine also acts as an antagonist at serotonin 5-HT2B and 5-HT2A receptors with high and moderate binding affinity, respectively, as well as it binds to the histamine H1 receptors. It shows a lower binding affinity to the serotonin 5-HT2C and α1A-adrenergic receptors and has no appreciable affinity for cholinergic muscarinic receptors.

Other Products detailed in the report…

Treatment-resistant Depression (TRD) Market Outlook

The report’s Treatment-resistant Depression (TRD) market outlook helps to understand the historic, current better, and forecasted Treatment-resistant Depression (TRD) market trends by analyzing the impact of current therapies on the market, unmet needs, SWOT analysis, and demand for better technology.

 

This segment gives a holistic analysis of the Treatment-resistant Depression (TRD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

 

According to DelveInsight, the Treatment-resistant Depression (TRD) market in 7MM is expected to grow steadily during the study period 2019–2032.

 

Various new therapies are in development, focusing on alleviating the limitations of the currently approved drugs. Some of the most prominent ones include AXS-05 (Axsome Therapeutics), Cariprazine (AbbVie), Esketamine DPI (Celon Pharma), AV-101 (VistaGen Therapeutics), REL-1017 (Relmada Therapeutics, Inc./Syneos Health ), MIJ821 (Novartis Pharmaceuticals ), among others. The market is poised to take off with novel candidates and regulators facilitating drug development with various designations, including Breakthrough Therapy, Orphan Drug Designation, etc.

 

In addition, market analysis shows immense Go-To-Market challenges such as manufacturing and commercialization strategies, pricing decisions, reimbursement negotiations, making the Treatment-resistant Depression (TRD) market one of the trickiest to navigate through.

 

SPRAVATO became the first nasal spray that received marketing approval from European Commission. However, European market access has become strained as NICE (HTA body of the UK) expressed concern about the clinical benefit and cost-effectiveness of SPRAVATO. NICE claimed that the advantages of SPRAVATO have not been compared directly, and hence unclear if improvements in symptoms will be sustained following a course or not. This is likely to limit the uptake of SPRAVATO in the UK market. Thus, upcoming therapies like AXS-05 and others must be cautious with pricing decisions and market access strategies for a successful launch across geographies.

 

Key Findings

This section includes a glimpse of the Treatment-resistant Depression (TRD) market in 7MM.

 

Treatment-resistant Depression (TRD) market size in the seven major markets was USD 2,441.9 million in 2021.

 

The United States Market Outlook

This section provides the total Treatment-resistant Depression (TRD) market size and market size by therapies in the United States.

 

EU-5 Countries: Market Outlook

The total Treatment-resistant Depression (TRD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Germany accounts for the largest market size for Treatment-resistant Depression (TRD) in EU5, followed by the United Kingdom, France, Spain, and Italy.

 

Japan: Market Outlook

The total Treatment-resistant Depression (TRD) market size and market size by therapies in Japan are provided in this section.

Treatment-resistant Depression (TRD) Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers the Treatment-resistant Depression (TRD) market uptake by drugs, patient uptake by therapies, and sales of each drug.

 

This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Treatment-resistant Depression (TRD) Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Treatment-resistant Depression (TRD) key players involved in developing targeted therapeutics.

 

Major market players include Axsome Therapeutics, AbbVie, Celon Pharma, Novartis Pharmaceuticals, among others.

 

Pipeline Development Activities

The report covers collaborations, acquisitions, mergers, licensing, and patent details for Treatment-resistant Depression (TRD) emerging therapies.

 

In June 2021, Gedeon Richter Plc. announced the extension of its existing licensing agreement with AbbVie, originally dated 2004, to develop and commercialize its own-developed molecule, cariprazine. The initial agreement covered the territories of the US and Canada and was extended in 2019 to include certain countries in Latin America. The present deal further expands the geographic scope of the cooperation to include Japan and Taiwan.

Reimbursement Scenario in Treatment-resistant Depression (TRD)

Proactively approaching reimbursement can positively impact both during the early stages of product development and after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with better market access can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Treatment-resistant Depression (TRD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Treatment-resistant Depression (TRD) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Treatment-resistant Depression (TRD) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Treatment-resistant Depression (TRD), explaining its causes, signs and symptoms, physiology, and currently available therapies.
  • Comprehensive insight has been provided into the Treatment-resistant Depression (TRD) epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Treatment-resistant Depression (TRD) is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Treatment-resistant Depression (TRD) market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Treatment-resistant Depression (TRD) market.

Report Highlights

  • In the coming years, the Treatment-resistant Depression (TRD) market is set to change due to the rising awareness of the disease, the development of diagnostic techniques, and the favorable environment from regulators for innovative first-in-class curative drugs that are likely to expand the market’s size and enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Treatment-resistant Depression (TRD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Treatment-resistant Depression (TRD). The launch of emerging therapies will significantly impact the Treatment-resistant Depression (TRD) market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Treatment-resistant Depression (TRD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Treatment-resistant Depression (TRD) Pipeline Analysis
  • Treatment-resistant Depression (TRD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Treatment-resistant Depression (TRD) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Treatment-resistant Depression (TRD) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Treatment-resistant Depression (TRD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness

Key Questions

Market Insights:

  • What was the Treatment-resistant Depression (TRD) Market share (%) distribution in 2019, and how would it look in 2032?
  • What would be the Treatment-resistant Depression (TRD) total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
  • What are the key findings of the market across 7MM, and which country will have the largest Treatment-resistant Depression (TRD) market size during the forecast period (2019–2032)?
  • At what CAGR, the Treatment-resistant Depression (TRD) market is expected to grow by 7MM during the forecast period (2019–2032)?
  • What would be the Treatment-resistant Depression (TRD) market outlook across the 7MM during the forecast period (2019–2032)?
  • What would be the Treatment-resistant Depression (TRD) market growth till 2032, and what will be the resultant market size in the year 2032?

 

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of Treatment-resistant Depression (TRD)?
  • What is the historical Treatment-resistant Depression (TRD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Treatment-resistant Depression (TRD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population for Treatment-resistant Depression (TRD)?
  • Out of all 7MM countries, which country would have the largest prevalent population of Treatment-resistant Depression (TRD) during the forecast period (2019–2032)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2019–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Treatment-resistant Depression (TRD) along with the approved therapy?
  • What are the current treatment guidelines for treating Treatment-resistant Depression (TRD) in the US, Europe, and Japan?
  • What is the Treatment-resistant Depression (TRD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Treatment-resistant Depression (TRD)?
  • How many therapies are developed by each company for the treatment of Treatment-resistant Depression (TRD)?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Treatment-resistant Depression (TRD)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to Treatment-resistant Depression (TRD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What clinical studies are going on for Treatment-resistant Depression (TRD) and its status?
  • What have key designations been granted for the emerging therapies for Treatment-resistant Depression (TRD)?
  • What are the global historical and forecasted markets for Treatment-resistant Depression (TRD)?

Reasons to buy

  • The report will help develop business strategies by understanding trends shaping and driving the Treatment-resistant Depression (TRD) market.
  • To understand the future market competition in the Treatment-resistant Depression (TRD) market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Treatment-resistant Depression (TRD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Treatment-resistant Depression (TRD) market.
  • To understand the future market competition in the Treatment-resistant Depression (TRD) market.

1. Key Insights

2. Report Introduction

3. Treatment-resistant Depression (TRD) Market Overview at a Glance

3.1. Market Share (%) Distribution of Treatment-resistant Depression (TRD) in 2019

3.2. Market Share (%) Distribution of Treatment-resistant Depression (TRD) in 2032

4. Executive Summary of Treatment-resistant Depression (TRD)

5. Disease Background and Overview

5.1. Introduction

5.2. Defining Treatment-resistant Depression

5.3. Clinical Manifestations

5.4. Risk Factors

5.5. Pathogenesis

5.6. Genetics of Treatment-resistant Depression

5.7. Diagnosis

5.7.1. Diagnostic Features

5.8. Diagnostic Guidelines

5.8.1. Diagnostic Criteria of Major Depressive Disorder According to ICD-11

5.8.2. DSM-V: Diagnostic Criteria - Major Depressive Disorder

5.8.3. Clinical Guidelines for the Management of Treatment-resistant Depression: French Recommendations from Experts, the French Association for Biological Psychiatry and Neuropsychopharmacology, and the Fondation FondaMental

5.9. Differential Diagnosis

5.10. Treatment and Management

5.11. Treatment Guidelines

5.11.1. Clinical Guidelines for the Management of Treatment-resistant Depression: French Recommendations from Experts, the French Association for Biological Psychiatry and Neuropsychopharmacology, and the Fondation FondaMental

5.11.2. NICE Guideline: Depression in adults; Treatment and Management

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Population of Treatment-resistant Depression (TRD)

6.3. Assumptions and Rationale

6.4. The United States

6.4.1. Total Diagnosed Prevalent Cases of Treatment-resistant Depression (TRD) in the United States

6.4.2. Gender-specific Cases of Treatment-resistant Depression (TRD) in the United States

6.4.3. Age-specific Cases of Treatment-resistant Depression (TRD) in the United States

6.5. EU-5

6.5.1. Total Diagnosed Prevalent Cases of Treatment-resistant Depression (TRD) in EU-5

6.5.2. Gender-specific Cases of Treatment-resistant Depression (TRD) in EU-5

6.5.3. Age-specific Cases of Treatment-resistant Depression (TRD) in EU-5

6.6. Japan

6.6.1. Total Diagnosed Prevalent Cases of Treatment-resistant Depression (TRD) in Japan

6.6.2. Gender-specific Cases of Treatment-resistant Depression (TRD) in Japan

6.6.3. Age-specific Cases of Treatment-resistant Depression (TRD) in Japan

7. Patient Journey

8. Marketed Products

8.1. Symbyax: Eli Lilly and Company

8.1.1. Product Description

8.1.2. Mechanism of Action

8.1.3. Regulatory Milestones

8.1.4. Generic Availability

8.1.5. Safety and Efficacy

8.1.6. Side effects

8.1.7. Product Profile

8.2. Spravato: Johnson & Johnson

8.2.1. Product Description

8.2.2. Mechanism of Action

8.2.3. Regulatory Milestones

8.2.4. Other Development Activities

8.2.5. Safety and Efficacy

8.2.6. Side effects

8.2.7. Product Profile

9. Emerging Therapies

9.1. Key Cross Competition

9.1.1. Other Assets

9.2. AXS-05: Axsome Therapeutics

9.2.1. Drug Description

9.2.2. Regulatory Milestones

9.2.3. Other Development Activities

9.2.4. Clinical Development

9.2.5. Clinical Trials Information

9.2.6. Safety and Efficacy

9.2.7. Product Profile

9.3. VRAYLAR (Cariprazine): AbbVie

9.3.1. Drug Description

9.3.2. Other Development Activities

9.3.3. Clinical Development

9.3.4. Clinical Trials Information

9.3.5. Safety and Efficacy

9.3.6. Product Profile

9.4. Esketamine DPI: Celon Pharma

9.4.1. Drug Description

9.4.2. Clinical Development

9.4.3. Clinical Trials Information

9.4.4. Safety and Efficacy

9.4.5. Product Profile

9.5. REL-1017: Relmada Therapeutics

9.5.1. Drug Description

9.5.2. Regulatory Milestones

9.5.3. Clinical Development

9.5.4. Clinical Trials Information

9.5.5. Safety and Efficacy

9.5.6. Product Profile

9.6. COMP360 (Psilocybin): COMPASS Pathways

9.6.1. Drug Description

9.6.2. Other Development Activities

9.6.3. Clinical Development

9.6.4. Clinical Trials Information

9.6.5. Safety and Efficacy

9.6.6. Product Profile

9.7. MIJ821: Novartis

9.7.1. Drug Description

9.7.2. Other Development Activities

9.7.3. Clinical Development

9.7.4. Clinical Trials Information

9.7.5. Safety and Efficacy

9.7.6. Product Profile

10. Other Promising Therapies

10.1. Liafensine (DB104): Denovo Biopharma

10.1.1. Drug Description

10.1.2. Other Development Activities

10.1.3. Clinical Development

10.1.4. Clinical Trials Information

10.1.5. Safety and Efficacy

10.1.6. Product Profile

10.2. MK-1942: Merck Sharp and Dohme Corp

10.2.1. Drug Description

10.2.2. Other Development Activities

10.2.3. Clinical Development

10.2.4. Clinical Trial Information

10.2.5. Safety and Efficacy

10.2.6. Product Profile

10.3. NV5138: Navitor Pharmaceuticals, Inc./Supernus Pharmaceuticals, Inc.

10.3.1. Drug Description

10.3.2. Other Development Activities

10.3.3. Regulatory Milestones

10.3.4. Clinical Development

10.3.5. Clinical Trial Information

10.3.6. Safety and Efficacy

10.3.7. Product Profile

10.4. TS161: Taisho Pharmaceutical Co., Ltd

10.4.1. Drug Description

10.4.2. Clinical Development

10.4.3. Clinical Trial Information

10.4.4. Safety and Efficacy

10.4.5. Product Profile

10.5. ANC-501: Ancora Bio/Aditum Bio

10.5.1. Drug Description

10.5.2. Other Development Activities

10.5.3. Clinical Development

10.5.4. Clinical Trials Information

10.5.5. Safety and Efficacy

10.5.6. Product Profile

10.6. AV-101: VistaGen Therapeutics

10.6.1. Drug Description

10.6.2. Other Development Activities

10.6.3. Clinical Development

10.6.4. Clinical Trials Information

10.6.5. Product Profile

10.7. PH10: VistaGen Therapeutics

10.7.1. Drug Description

10.7.2. Mechanism of Action

10.7.3. Regulatory Milestones

10.7.4. Safety and Efficacy

10.7.5. Product Profile

11. Treatment-resistant Depression (TRD): 7 Major Market Analysis

11.1. Key Findings

11.2. Market Size of Treatment-resistant Depression (TRD) in 7MM

11.3. Market Outlook

11.4. United States Market Size

11.4.1. Total Market Size of Treatment-resistant Depression (TRD) in the United States

11.4.2. Market Size of Treatment-resistant Depression (TRD) by Therapies

11.5. EU-5 Market

11.5.1. Total Market Size of Treatment-resistant Depression (TRD) in EU-5

11.5.2. Germany

11.5.3. France

11.5.4. Italy

11.5.5. Spain

11.5.6. United Kingdom

11.6. Japan

11.6.1. Total Market Size of Treatment-resistant Depression (TRD) in Japan

11.6.2. Market Size of Treatment-resistant Depression (TRD) by Therapies in Japan

12. SWOT Analysis

13. Unmet Needs

14. KOL Views

15. Market Access and Reimbursement

16. Appendix

16.1. Bibliography

16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Table

Table 1: Summary of Treatment-resistant Depression, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Thase and Rush Staging Method

Table 3: Massachusetts General Hospital Staging Method

Table 4: The European Staging Method

Table 5: Risk factors involved in Treatment-resistant Depression

Table 6: Severity/course specifier

Table 7: Major Depressive Disorder Diagnostic Criteria According to DSM-V

Table 8: Differential Diagnosis of Treatment-resistant Depression

Table 9: Five Main Treatment Strategies to overcome lack of response to antidepressant therapy

Table 10: Treatment Algorithm for Treatment-resistant Depression

Table 11: Indications for hospitalization

Table 12: Adjuvant treatments

Table 13: Treatments with an ADT action

Table 14: Limited Response and Treatment-resistant Depression

Table 15: Total Prevalent Population of TRD in 7MM (2019–2032)

Table 16: Total Prevalent Cases of TRD in the United States (2019–2032)

Table 17: Gender-specific Cases of TRD in the United States (2019–2032)

Table 18: Age-specific Cases of TRD in the United States (2019–2032)

Table 19: Total Diagnosed Prevalent Cases of TRD in EU5 (2019–2032)

Table 20: Gender-specific Cases of TRD in EU-5 (2019–2032)

Table 21: Age-specific Cases of TRD in EU-5 (2019–2032)

Table 22: Total Prevalent Cases of TRD in Japan (2019–2032)

Table 23: Gender-specific Cases of TRD in Japan (2019–2032)

Table 24: Age-specific Cases of TRD in Japan (2019–2032)

Table 25: Mechanism of Action of AXS-05

Table 26: AXS-05, Clinical Trial Description, 2022

Table 27: Cariprazine, Clinical Trial Description, 2022

Table 28: Esketamine DPI, Clinical Trial Description, 2022

Table 29: REL-1017, Clinical Trial Description, 2021

Table 30: COMP360 (Psilocybin), Clinical Trial Description, 2022

Table 31: IMR-687, Clinical Trial Description, 2022

Table 32: DB104, Clinical Trial Description, 2022

Table 33: MK-1942, Clinical Trial Description, 2022

Table 34: NK5-138, Clinical Trial Description, 2022

Table 35: NK5-138, Clinical Trial Description, 2022

Table 36: DB104, Clinical Trial Description, 2022

Table 37: AV-101, Clinical Trial Description, 2022

Table 38: Seven Major Market Size of TRD in USD million (2019–2032)

Table 39: The US Market Size of TRD in USD million (2019–2032)

Table 40: The US Market Size of TRD by Therapies in USD million (2019–2032)

Table 41: EU-5 Market Size of TRD in USD million (2019–2032)

Table 42: Germany Market Size of TRD by Therapies in USD million (2019–2032)

Table 43: France Market Size of TRD by Therapies in USD million (2019–2032)

Table 44: Italy Market Size of TRD by Therapies in USD million (2019–2032)

Table 45: Spain Market Size of TRD by Therapies in USD million (2019–2032)

Table 46: The UK Market Size of TRD by Therapies in USD million (2019–2032)

Table 47: Japan Market Size of TRD in USD million (2019–2032)

Table 48: Japan Market Size of TRD by Therapies in USD million (2019–2032)

Table 49: Coverage for Spravato

Table 50: G Codes to Report Spravato on Medicare Claims

Table 51: G Codes to Report Spravato on Non-medicare Claim

Table 52: National Drug Code

List of Figures

Figure 1: Clinical Manifestations in Treatment-resistant Depression

Figure 2: Difference between ICD-11 and DSM-V

Figure 3: Total Prevalent Population of TRD (2019–2032)

Figure 4: Total Prevalent Cases of TRD in the US (2019–2032)

Figure 5: Gender-specific Cases of TRD in the United States (2019–2032)

Figure 6: Age-specific Cases of TRD in the United States (2019–2032)

Figure 7: Total Diagnosed Prevalent Cases of TRD in EU5 (2019–2032)

Figure 8: Gender-specific Cases of TRD in EU-5 (2019–2032)

Figure 9: Age-specific Cases of TRD in EU-5 (2019–2032)

Figure 10: Total Prevalent Cases of TRD in Japan (2019–2032)

Figure 11: Gender-specific Cases of TRD in Japan (2019–2032)

Figure 12: Age-specific Cases of TRD in Japan (2019–2032)

Figure 13: Seven Major Market Size of TRD in USD million (2019–2032)

Figure 14: The US Market Size of TRD in USD million (2019–2032)

Figure 15: The US Market Size of TRD by Therapies (2019–2032)

Figure 16: EU-5 Market Size of TRD in USD million (2019–2032)

Figure 17: Germany Market Size of TRD by Therapies (2019–2032)

Figure 18: France Market Size of TRD by Therapies (2019–2032)

Figure 19: Italy Market Size of TRD by Therapies (2019–2032)

Figure 20: Spain Market Size of TRD by Therapies (2019–2032)

Figure 21: The United Kingdom Market Size of TRD by Therapies (2019–2032)

Figure 22: Japan Market Size of TRD in USD million (2019–2032)

Figure 23: Japan Market Size of TRD by Therapies (2019–2032)

Eli Lilly and Company
Johnson & Johnson
Axsome Therapeutics
AbbVie
Celon Pharma
Relmada Therapeutics
COMPASS Pathways
Novartis
Denovo Biopharma
Merck Sharp and Dohme Corp
Navitor Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.
Taisho Pharmaceutical Co., Ltd
Ancora Bio
Aditum Bio
VistaGen Therapeutics
VistaGen Therapeutics

 

Forward to Friend

Need A Quote